Insurance companies are not paying for Repatha and Praluent

Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.

March 8, 2017- Interviewed by Steven E. Greer, MD

We interviewed cardiologist William O’Neill, MD about his personal need for the cholesterol-lowering, large-molecule, antibody drug from Amgen, branded as Repatha. Despite the drug being extremely effective, insurance companies are more and more refusing to pay for it.

This entry was posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *